wenty-five to 35 percent of cases of medulloblastoma, the most common malignant brain tumor of childhood, occur in children younger than three years of age. 1 In contrast to the prognosis for older children, the prognosis for infants and young children treated with surgery, radiotherapy, and chemotherapy remains poor: survival rates have been static for two decades. 2 The lack of progress relates not only to the frequent occurrence of metastases at diagnosis but also to the biology of medulloblastoma in young children. [3] [4] [5] In addition, the susceptibility of the immature brain to radiotherapy-induced cognitive deficits, [6] [7] [8] which increase for years after radiotherapy, 9,10 has set age limitations on the use of radiotherapy in children. Some patients have been cured by postoperative chemotherapy alone, [11] [12] [13] [14] but survival rates after chemotherapy, with or without radiotherapy, remain unsatisfactory at 25 to 45 percent.
A pilot trial showed that postoperative chemotherapy can delay the start of radiotherapy. 15 In the present trial we investigated whether intensive postoperative chemotherapy alone improves survival and cognitive function in young children. Instead of radiotherapy, we administered intraventricular methotrexate through an implanted subcutaneous reservoir, with the aim of prolonging cytotoxic methotrexate levels in the cerebrospinal fluid by giving repeated small single doses. 16 Patients underwent detailed neuropsychological testing and were monitored for leukoencephalopathy, which can be a toxic effect of methotrexate. 17 
patients
From April 1992 through December 1997, we registered 62 children with medulloblastoma who were under three years of age. We excluded eight patients because they had a different histopathological diagnosis in central review, eight because they had different chemotherapy or primary radiotherapy or both, and three because they had no therapy or were lost to follow-up. The remaining 43 patients (28 boys and 15 girls) were treated in 31 pediatric oncology centers. Informed consent was obtained from legal representatives of all patients.
surgery
The maximum possible surgical removal of the primary tumor, depending on the anatomical location of the tumor and the condition of the child, was recommended. The extent of resection was assessed by magnetic resonance imaging (MRI) or computed tomography (CT) performed within 72 hours after surgery. After histologic confirmation of the diagnosis, an intraventricular subcutaneous reservoir (an Ommaya or a Rickham reservoir) was implanted in the anterior horn of a lateral ventricle.
pathological analysis
The diagnosis of medulloblastoma was histologically confirmed in all 43 patients by a central pathology laboratory. Tumors were classified according to the World Health Organization classification of brain tumors as classic medulloblastoma (23 patients) or desmoplastic medulloblastoma (20 patients). Other histologies (six atypical teratoid rhabdoid tumors, one ependymoblastoma, and one choroid-plexus carcinoma) were excluded. Cytospin preparations of lumbar cerebrospinal fluid were available from 29 patients for the analysis of tumor cells.
treatment
Chemotherapy was started two to four weeks after surgery. Children received three two-month cycles of chemotherapy, each consisting of cyclophosphamide, methotrexate (followed by leucovorin rescue after 42 hours), vincristine, carboplatin, and etoposide (Table 1) . Doses of cyclophosphamide, t methods * One two-month cycle of intraventricular and systemic chemotherapy consisted of four treatments. The second and third cycles of chemotherapy were started at weeks 10 and 19, respectively. Treatment was finished if patients were in complete remission after three cycles of chemotherapy. Complete response was defined as the total disappearance of residual tumors or macroscopic metastasis during chemotherapy or at the end of treatment. Partial response was defined as a decrease of at least 25 percent of the tumor size, stable disease as a decrease or increase of less than 25 percent, and progressive disease as an increase of at least 25 percent.
Before each treatment, the complete blood count, electrolyte levels, and creatinine concentration were determined, and liver-function tests were performed. Serum concentrations of methotrexate were measured at standard intervals until levels were below 0.25 µ mol per liter.
Intraventricular administration of methotrexate was omitted in patients with suspected infection of the central nervous system, thrombocytopenia (a platelet count of less than 30,000 per cubic millimeter), or evidence of disturbed circulation of cerebrospinal fluid. In patients with a ventriculoperitoneal or ventriculoatrial shunt, intraventricular administration was permitted only in cases of metastatic disease. To determine the extent and course of leukoencephalopathy, cranial MRI findings obtained during and after treatment were classified independently by two reviewers according to the classification methods of Fazekas. 19 After treatment, legal representatives of all surviving children were informed, and we requested permission to perform a neuropsychological examination. All children for whom consent was obtained underwent detailed age-adapted neuropsychological examination, performed by the same psychologist. The intelligence levels of patients were determined by the Colored Progressive Matrices test and the Kaufmann-Assessment Battery for Children. Sensorimotor abilities were measured by the Developmental Test of Visual-Motor Integration.
* Patients were categorized in three groups according to initial tumor stage: complete resection (17 patients) and incomplete resection (14 patients) without macroscopic metastases (stage M0 or M1), and macroscopic cranial or spinal metastases regardless of residual tumor, stage M2 or M3 (12 patients). Response to chemotherapy was assessable in 26 patients with postoperative residual tumors, metastases, or both. Patients with early response followed by progressive disease during chemotherapy were classified as not having a response. Because of rounding, percentages may not sum to the total. † Dissemination of tumor cells into the cerebrospinal fluid was confirmed in samples from 9 of 29 patients. (Table 2) .
progression-free and overall survival
The estimated five-year progression-free and overall survival rates among the 43 children were 58±9 percent and 66±7 percent, respectively. In children who had complete resection, those who had residual tumor, and those who had stage M2 or M3 metastatic disease, the five-year progression-free and overall survival rates were 82±9 percent and 93±6 percent, 50±13 percent and 56±14 percent, and 33±14 percent and 38±15 percent, respectively (Fig. 1) . The median follow-up times of surviving patients in these three groups were 7.1 years (range, 3.6 to 9.2), 6.1 years (2.7 to 10.2), and 5.5 years (4.2 to 7.3), respectively. In 31 patients without macroscopic metastases, differences between groups with complete and incomplete surgical resection were significant for overall survival (P=0.009) and for progression-free survival (P=0.04). Of 17 children without residual postoperative tumor, 14 remained in complete continuous remission without radiotherapy. The five-year progression-free and overall survival rates among 31 patients without macroscopic metastases were 68±8 percent and 77±8 percent, and 21 of these 31 patients remain in continuous remission without radiotherapy. Differences between nonmetastatic and metastatic (stage M2 or M3) disease were significant (P<0.002). Of 12 patients with initial macroscopic metastases, 3 achieved a continuous remission without radiotherapy. Twenty patients with desmoplastic medulloblastoma had significantly better five-year progression-free and overall survival rates (85±8 percent and 95±5 percent) than did 23 patients with classic results Progression-free survival (Panel A) and overall survival (Panel B) were significantly different among 14 children with and 17 children without residual tumors and also among 12 children with and 31 children without metastases. Results were encouraging, especially in subgroups without macroscopic metastases, in which 21 of 31 children remained in complete continuous remission without radiotherapy. Only two patients had a tumor relapse more than two years after chemotherapy. The new england journal of medicine 982 medulloblastoma (34±10 percent and 41±11 percent, P<0.001 for both progression-free survival and overall survival) (Fig. 2) .
response to chemotherapy
The overall response rate was 62 percent in 26 patients with measurable disease after initial surgery (residual tumor or metastasis) ( Table 2 ). In three of nine patients, cerebrospinal fluid was cleared of tumor cells (stage M1) during chemotherapy. No tumor relapse occurred during chemotherapy in patients without measurable disease after surgery. The five-year progression-free survival rate among 29 patients without evidence of disease at the end of chemotherapy was higher than the rate in 14 patients with less than complete remission after chemotherapy (68±9 percent vs. 36±13 percent, P<0.002). The overall survival rate was also higher among the patients without evidence of disease than among the patients with less than complete remission (77±8 percent vs. 34±13 percent, P<0.001).
resistant disease and relapses
At the end of the designated chemotherapy, 14 patients had residual disease and received further chemotherapy, radiotherapy, or both. Of these patients, 10 died of progressive disease. Of the remaining four patients, three reached complete remission and one has had stable disease for seven years after further chemotherapy; two patients received additional radiotherapy.
Tumor relapses occurred in 9 of 29 patients without residual disease after chemotherapy. In three patients the tumor relapsed locally, whereas three patients had combined local and stage M2 or M3 relapses and three patients had distant relapses only. After 15.4 months, 75 percent of all patients had no progression or relapse. The relapses that did occur were observed within 2 to 75 months; only two patients had a relapse more than 2 years after initial diagnosis. In total, 16 patients received further treatment at progression or relapse, and 3 patients received no further treatment. Eight of these 16 patients were successfully treated by chemotherapy (2 patients), radiotherapy (2), or both (4, including high-dose chemotherapy in 2 patients). Six of the 16 children (38 percent) are alive after the inclusion of radiotherapy in the salvage therapy. There was no major unexpected toxicity from systemic chemotherapy. Myelotoxicity was the most frequently reported side effect; patients required a median of 2 erythrocyte transfusions (range, 0 to 5) during chemotherapy. Admission for neutropenia and fever was common (median, 3 episodes; range, 0 to 6). No treatment-related deaths or lethal infections occurred. Toxicity data for intraventricular chemotherapy were available from 38 patients. No toxicity was reported for 33 patients, whereas 2 patients had cerebral seizures that were temporally unrelated to the administration of methotrexate. One patient had a cerebrospinal fluid infection with Staphylococcus epidermidis . In two of six patients with a ventriculoperitoneal shunt, abdominal ascites developed (no infectious agent was identified); in one child, episodes of ascites did not recur after discontinuation of intraventricular methotrexate, whereas in the other child ascites ceased after removal of the shunt. Methotrexate in the ventricular cerebrospinal fluid was measured in 38 patients 24 hours after each application, and no toxic levels (>5 µmol per liter) were found. In two patients, lumbar cerebrospinal fluid levels of methotrexate were analyzed routinely 24 hours after administration, and levels between 0.21 and 2.2 µ mol per liter were documented.
T 2 -weighted cranial MRIs of 23 children were available for the evaluation of leukoencephalopathy during and after treatment. Leukoencephalopathy was not detected in four patients. In 19 patients, all without related symptoms, leukoencephalopathy was classified as mild (spotted, circumscribed lesions in 4 children), moderate (patchy lesions in 9 children), or severe (confluent lesions in 6 children). The maximal grade of leukoencephalopathy was observed one year after treatment. At further follow-up, the severity of leukoencephalopathy decreased to a lower grade in 10 patients and remained stable in 8 patients. One patient was not available for follow-up. A significant correlation between the grade of leukoencephalopathy and the cumulative dose of intraventricular methotrexate was found (correlation coefficient, 0.53; P<0.01), but there was no correlation between the leukoencephalopathy grade and doses of intravenous methotrexate. In six assessable children who had received craniospinal radiotherapy after the application of methotrexate, grade 2 or 3 leukoencephalopathy developed.
neuropsychological evaluation
Detailed neuropsychological follow-up was performed in 14 patients at a median of 4.8 years (range, 3.9 to 8.1) after diagnosis. The mean IQ was significantly lower than in healthy controls within the same age group (T scores, 45±9 vs. 53±8 for the Colored Progressive Matrices test; 38±10 vs. 50±7 for the Kaufmann-Assessment Battery for Children; and 39±8 vs. 52±13 for the Visual-Motor Integration test; P<0.001) (Fig. 3) . The general intelligence of the children who did not receive radiotherapy The results of IQ tests are expressed as T scores and IQ points. Neurocognitive deficits in children treated with intraventricular and systemic chemotherapy were less pronounced than the deficits in children receiving radiotherapy. Six children received radiotherapy as salvage therapy after systemic and intraventricular chemotherapy, 11 received systemic chemotherapy and radiotherapy but no intraventricular methotrexate, 14 received systemic chemotherapy and intraventricular methotrexate, and 3 received systemic chemotherapy but no intraventricular methotrexate or radiotherapy. There were 23 children in the control group. CPM denotes Colored Progressive Matrices test, VMI Developmental Test of Visual-Motor Integration, and K-ABC Kaufmann-Assessment Battery for Children. The new england journal of medicine 984 was significantly higher than the general intelligence of children in a former trial who had received radiotherapy but had not been treated with intraventricular methotrexate 15 (Colored Progressive Matrices test, 45±9 vs. 36±5; P<0.005). In addition, there was a trend toward different scores on the Kaufmann-Assessment Battery for Children and the Visual-Motor Integration test between these two groups and a trend toward higher T scores for all applied tests in children receiving systemic chemotherapy only, as compared with children treated with systemic and intraventricular chemotherapy (Fig. 3 ). Patients treated with radiotherapy after chemotherapy had the lowest IQs (Colored Progressive Matrices test, 32±7; Kaufmann-Assessment Battery for Children, 28±11; and Visual-Motor Integration test, 33±11).
Our study shows that young children with medulloblastoma can enjoy a lengthy remission after treatment with postoperative chemotherapy alone. The estimated survival rates among the 43 patients (fiveyear progression-free survival, 58±9 percent; overall survival, 66±7 percent) compare favorably with the results of other studies in which combined radiotherapy and chemotherapy or chemotherapy alone was used. The results of our study are especially promising for young children without metastases or postoperative residual tumors (progressionfree survival, 82±9 percent; overall survival, 93±6 percent). Likewise, the outcome of children without macroscopic metastases, regardless of the presence or absence of postoperative residual tumors, is encouraging, reaching five-year progression-free and overall survival rates of 68±8 percent and 77±8 percent, respectively. Radiotherapy was successfully averted in 20 of 31 patients who had no macroscopic metastases. Survival was significantly lower among patients with a stage M2 or M3 tumor (progression-free survival, 33±14 percent; overall survival, 38±15 percent). The identification of stage M1 and macroscopic metastases as strong adverse prognostic factors supports the stratification criteria currently applied in older children. 5 Other treatments are required for children with macroscopic metastases at diagnosis, but it is noteworthy that three children in this subgroup have remained in remission for more than five years without requiring radiotherapy. Although the presence of a postoperative residual tumor was not shown statistically to be an independent adverse prognostic factor, we believe that this presentation justifies maximal surgery at diagnosis. Given the small size of this study, we regard multivariate analysis as explorative, and P values as descriptive.
Overall response rates in our study (62 percent) compare favorably with rates reported previously. 12, 20 Notably, no tumor progression was observed during chemotherapy in the 31 children without initial macroscopic metastases. In contrast to other studies in which the risk of progression along the neuroaxis increased with the duration of chemotherapy, 21,22 our study involved chemotherapy that had a favorable safety profile.
Survival among patients in our pilot trial with delayed radiotherapy was poorer than among patients in the present trial, and no patient in the pilot trial received successful salvage therapy after relapse (overall survival rate, 71 percent and 45 percent for nonmetastatic disease without and with postoperative residual tumor, respectively, and 0 percent for patients with initial metastases). The psychological outcome and the school performance were worse in the survivors who received radiotherapy than in the children in the present trial. However, the two regimens differed not only in the use of radiotherapy and intraventricular methotrexate but also in the systemic chemotherapy (procarbazine, ifosfamide, and cytarabine were used in the pilot trial but not in the present study).
Desmoplastic medulloblastoma in older children is associated with a better survival, 23 but the relevance of desmoplasia in young children is unclear. In our study, the 20 children with desmoplastic histology had a better outcome than the 23 with classical medulloblastoma (progression-free survival, 85±8 percent vs. 34±10 percent; overall survival, 95±5 percent vs. 41±11 percent; P<0.001), and desmoplastic histology was identified as an independent favorable prognostic factor. These data suggest that the stratification of risk groups may be improved by consideration of desmoplasia in young children with medulloblastoma. In our study, an age of two years or less at diagnosis was a statistically significant adverse risk factor as compared with an age between two and three years.
Neurotoxicity after the administration of intrathecal methotrexate has been related to direct toxic effects and interference with metabolic pathways in the brain, 24 and cases of inadvertent intraparenchymal instillation of methotrexate have been described. 25 Therefore, toxicity and the neuropsycho- logical outcome were of special interest in our study.
No child had symptoms of methotrexate-induced neurotoxicity. Toxic methotrexate levels in cerebrospinal fluid were not reported. Chemical peritonitis developed during chemotherapy in two of six children with a ventriculoperitoneal shunt. Thus, intraventricular methotrexate cannot be recommended for children with a ventriculoperitoneal shunt lacking a device for transient shunt occlusion. Not unexpectedly, moderate to severe leukoencephalopathy was found in 15 of 23 patients. A significant correlation was found between the grade of leukoencephalopathy and the cumulative dose of intraventricular methotrexate, suggesting a dose-dependent effect of methotrexate on leukoencephalopathy. Leukoencephalopathy did not cause symptoms and was a transient phenomenon in 10 children.
After treatment, the results of all IQ tests (the Colored Progressive Matrices test, the KaufmannAssessment Battery for Children, and the Developmental Test of Visual-Motor Integration) were significantly lower than the results of the tests in healthy controls of the same age group, indicating that the disease itself, surgery, and chemotherapy have a negative effect on neurocognitive functions. However, the results of the Colored Progressive Matrices test in children treated with chemotherapy alone was significantly higher than the results of the test in patients in our previous trial who received radiotherapy but did not receive intraventricular methotrexate (45±9 vs. 36±5, P<0.005).
In conclusion, this study shows that lengthy remissions can be obtained in young children with medulloblastoma by intensive postoperative chemotherapy. Results are especially promising for patients without initial metastases, in whom radiotherapy should be reserved for salvage strategies at relapse.
